PMN
ProMIS Neurosciences, Inc.
Biotechnology
Market Cap$68M
5Y Perf.-95.7%
Build Your Comparison
Side-by-side financial analysisPMN
SAVA
Try popular comparisons:
Stock Comparison
PMN vs SAVA
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$64M
5Y Perf.+418.2%
PMN vs SAVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  PMN |  SAVA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $68M | $64M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-41M | $-106M |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $6M | $129M |
PMN vs SAVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PMN
SAVA
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| ProMIS Neuroscience… (PMN) | 100 | 4.3 | -95.7% |
| Cassava Sciences, I… (SAVA) | 100 | 518.2 | +418.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PMN vs SAVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PMN leads in 2 of 4 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Cassava Sciences, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇PMN emerged as the overall leader. Track its performance:
PMN
ProMIS Neurosciences, Inc.
The Income Pick
PMN carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 1.11
- Lower volatility, beta 1.11, current ratio 0.88x
- Beta 1.11, current ratio 0.88x
Best for: income & stability and sleep-well-at-night
SAVA
Cassava Sciences, Inc.
The Growth Play
SAVA is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth 77.6%
- -38.0% 10Y total return vs PMN's -91.4%
- -75.3% ROA vs PMN's -151.0%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  PMN | Beta 1.11 vs SAVA's 1.92 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PMN | -20.4% vs SAVA's -37.7% |
| Efficiency (ROA) |  SAVA | -75.3% ROA vs PMN's -151.0% |
PMN vs SAVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSAVALAGGINGPMN
PMNProMIS Neurosciences,…
1leads
SAVACassava Sciences, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs PMNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PMN1/1
Valuation MetricsMultiples, price ratios, and targets
SAVA1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SAVA5/5
Total Returns1Y, 3Y, 5Y total returns with dividends
SAVA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PMN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PMN and SAVA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$41M | -$110M |
| Net IncomeAfter-tax profit | -$41M | -$106M |
| Free Cash FlowCash after capex | -$35M | -$84M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +76.0% | +62.1% |
PMN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Market CapShares × price | $68M | $64M |
| Enterprise ValueMkt cap + debt − cash | $61M | -$65M |
| Trailing P/EPrice ÷ TTM EPS | -0.46x | -2.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | 0.42x |
| Price / FCFMarket cap ÷ FCF | — | — |
SAVA leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
SAVA leads this category, winning 5 of 5 comparable metrics.
Profitability & Efficiency
SAVA delivers a -95.8% return on equity — every $100 of shareholder capital generates $-96 in annual profit, vs $-2 for PMN. On the Piotroski fundamental quality scale (0–9), SAVA scores 2/9 vs PMN's 0/9, reflecting mixed financial health.
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| ROE (TTM)Return on equity | -2.4% | -95.8% |
| ROA (TTM)Return on assets | -151.0% | -75.3% |
| ROICReturn on invested capital | — | -6.3% |
| ROCEReturn on capital employed | -5.2% | -99.9% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$6M | -$129M |
| Cash & Equiv.Liquid assets | $6M | $129M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
SAVA leads this category, winning 5 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
SAVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SAVA five years ago would be worth $1,219 today (with dividends reinvested), compared to $363 for PMN. Over the past 12 months, PMN leads with a -20.4% total return vs SAVA's -37.7%. The 3-year compound annual growth rate (CAGR) favors SAVA at -27.9% vs PMN's -56.0% — a key indicator of consistent wealth creation.
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| YTD ReturnYear-to-date | +45.0% | -36.8% |
| 1-Year ReturnPast 12 months | -20.4% | -37.7% |
| 3-Year ReturnCumulative with dividends | -91.5% | -62.5% |
| 5-Year ReturnCumulative with dividends | -96.4% | -87.8% |
| 10-Year ReturnCumulative with dividends | -91.4% | -38.0% |
| CAGR (3Y)Annualised 3-year return | -56.0% | -27.9% |
SAVA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PMN and SAVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
PMN is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.92x |
| 52-Week HighHighest price in past year | $39.75 | $4.98 |
| 52-Week LowLowest price in past year | $6.27 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +26.0% | +26.5% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 42.7 |
| Avg Volume (50D)Average daily shares traded | 34K | 134K |
Evenly matched — PMN and SAVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PMN as "Buy" and SAVA as "Buy".
| Metric | PMNProMIS Neuroscien… | SAVACassava Sciences,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | — |
| # AnalystsCovering analysts | 2 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SAVA leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). PMN leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCassava Sciences, Inc. (SAVA)Leads 3 of 6 categories
Loading custom metrics...
PMN vs SAVA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PMN or SAVA a better buy right now?
Analysts rate ProMIS Neurosciences, Inc.
(PMN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PMN or SAVA?
Over the past 5 years, Cassava Sciences, Inc.
(SAVA) delivered a total return of -87. 8%, compared to -96. 4% for ProMIS Neurosciences, Inc. (PMN). Over 10 years, the gap is even starker: SAVA returned -38. 0% versus PMN's -91. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PMN or SAVA?
By beta (market sensitivity over 5 years), ProMIS Neurosciences, Inc.
(PMN) is the lower-risk stock at 1. 11β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 74% more volatile than PMN relative to the S&P 500.
04Which is growing faster — PMN or SAVA?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to -922. 2% for ProMIS Neurosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PMN or SAVA?
ProMIS Neurosciences, Inc.
(PMN) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PMN leads at 0. 0% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — PMN leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PMN or SAVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PMN or SAVA better for a retirement portfolio?
For long-horizon retirement investors, ProMIS Neurosciences, Inc.
(PMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PMN: -91. 4%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PMN and SAVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.